randomized phase 2 study of Docetaxel+CBDCA versus weekly Paclitaxel+CBDCA
Phase 2
- Conditions
- ovarian cancer
- Registration Number
- JPRN-C000000155
- Lead Sponsor
- Osaka Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
pregnant or nursing woman
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method quality of life ,safety